Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 197 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9, 15, 19 and 7 respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Chronic Kidney Disease (Chronic Renal Failure).

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Kidney Disease (Chronic Renal Failure) Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 9
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 10
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 11
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 14
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 18
Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 21
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 22
Acceleron Pharma, Inc. 22
Angion Biomedica Corp. 23
Astellas Pharma Inc. 24
AstraZeneca Plc 25
Bayer AG 26
Bio-inRen 27
BioAegis Therapeutics, Inc. 28
Boehringer Ingelheim GmbH 29
Bristol-Myers Squibb Company 30
Cellmid Limited 31
Complexa, Inc. 32
CTI BioPharma Corp. 33
Evotec AG 34
F. Hoffmann-La Roche Ltd. 35
Gilead Sciences, Inc. 36
GNI Group Ltd. 37
Intercept Pharmaceuticals, Inc. 38
Lupin Limited 39
Navya Biologicals Pvt Ltd 40
Nippon Zoki Pharmaceutical Co., Ltd. 41
Novartis AG 42
Otsuka Holdings Co., Ltd. 43
Prismic Pharmaceuticals, Inc. 44
Prolong Pharmaceuticals, LLC 45
ProMetic Life Sciences Inc. 46
Reata Pharmaceuticals, Inc. 47
Red Glead Discovery AB 48
RegenMedTX, LLC 49
Resverlogix Corp. 50
Sphaera Pharma Pvt. Ltd. 51
Stelic Institute & Co., Inc. 52
Taisho Pharmaceutical Co., Ltd. 53
Thrasos Therapeutics Inc. 54
Toray Industries, Inc. 55
VBS Pharmaceuticals 56
Vicore Pharma AB 57
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 64
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
(palmidrol + silibinin) - Drug Profile 72
ambrisentan - Drug Profile 73
ANG-3070 - Drug Profile 75
ANG-3281 - Drug Profile 76
ANG-3586 - Drug Profile 77
apabetalone - Drug Profile 78
AS-2444697 - Drug Profile 87
bardoxolone methyl - Drug Profile 88
BI-655088 - Drug Profile 93
BLR-400 - Drug Profile 94
BMS-986177 - Drug Profile 95
BRN-1889 - Drug Profile 96
C-21 - Drug Profile 97
CAB-101 - Drug Profile 99
calcium succinate - Drug Profile 100
CAR Peptide - Drug Profile 101
cardiotoxin - Drug Profile 102
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 103
CXA-10 - Drug Profile 104
dapagliflozin propanediol - Drug Profile 106
Drug for Kidney Diseases - Drug Profile 113
F-351 - Drug Profile 114
finerenone - Drug Profile 116
INT-767 - Drug Profile 118
KBP-5074 - Drug Profile 119
LHW-090 - Drug Profile 120
NAV-003 - Drug Profile 121
NZ-419 - Drug Profile 122
obinutuzumab - Drug Profile 123
pacritinib - Drug Profile 130
PBI-4050 - Drug Profile 141
PBI-4419 - Drug Profile 146
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 147
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 148
Sanguinate - Drug Profile 150
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile 152
Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease and Hypertension - Drug Profile 153
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 154
Small Molecules for Chronic Kidney Disease - Drug Profile 155
Small Molecules for Chronic Kidney Disease - Drug Profile 156
Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile 157
sotatercept - Drug Profile 158
SP-20103 - Drug Profile 163
SPR-494 - Drug Profile 164
STNM-310 - Drug Profile 165
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 166
Synthetic Peptides for Chronic Kidney Disease - Drug Profile 167
TNT-009 - Drug Profile 168
tolvaptan - Drug Profile 170
torsemide ER - Drug Profile 174
TRC-101 - Drug Profile 175
TS-143 - Drug Profile 176
Vida-5 - Drug Profile 177
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 178
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 181
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 182
Featured News & Press Releases 182
Appendix 192
Methodology 192
Coverage 192
Secondary Research 192
Primary Research 192
Expert Panel Validation 192
Contact Us 192
Disclaimer 193

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2016 13
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Development by Companies, H2 2016 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Products under Development by Companies, H2 2016 22
Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2016 25
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H2 2016 26
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H2 2016 27
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H2 2016 28
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H2 2016 29
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H2 2016 30
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H2 2016 31
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics, Inc., H2 2016 32
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 33
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2016 34
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Limited, H2 2016 35
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa, Inc., H2 2016 36
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp., H2 2016 37
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H2 2016 38
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 39
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences, Inc., H2 2016 40
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd., H2 2016 41
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 42
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Limited, H2 2016 43
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd, H2 2016 44
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H2 2016 45
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H2 2016 46
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 47
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 48
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 49
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc., H2 2016 50
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 51
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H2 2016 52
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by RegenMedTX, LLC, H2 2016 53
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp., H2 2016 54
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 55
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute & Co., Inc., H2 2016 56
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2016 57
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Thrasos Therapeutics Inc., H2 2016 58
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H2 2016 59
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VBS Pharmaceuticals, H2 2016 60
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H2 2016 61
Assessment by Monotherapy Products, H2 2016 62
Assessment by Combination Products, H2 2016 63
Number of Products by Stage and Target, H2 2016 65
Number of Products by Stage and Mechanism of Action, H2 2016 69
Number of Products by Stage and Route of Administration, H2 2016 73
Number of Products by Stage and Molecule Type, H2 2016 75
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2016 182
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..1), H2 2016 183
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..2), H2 2016 184
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2016 185